Skip to main content

Table 2 The characteristics of the patients with HCC or ICC

From: Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma

Variables HCC ICC p value
Development set
N 202 146  
Age (years) 54.3 ± 9.4 57.7 ± 9.3 0.001
BMI (kg/m2) 24.2 ± 3.0 24.4 ± 3.7  0.487
Sex (Male, %) 163 (80.7) 87 (59.6)  < 0.001
HBsAg (%) 157 (77.7) 40 (27.4)  < 0.001
Hepatitis C (%) 17 (8.4) 2 (1.4) 0.004
Cirrhosis (%) 167 (82.7) 36 (24.5)  < 0.001
Tumor number (Multiple, %) 36 (17.8) 7 (4.8)  < 0.001
The largest nodule diameter (cm) 4.9 ± 3.3 6.0 ± 2.7 0.002
Capsule (Incomplete, %) 11 (5.4) 17 (11.6) 0.036
WBC (× 109/L) 5.46 ± 1.92 6.84 ± 2.04  < 0.001
Haemoglobin (g/L) 142.5 ± 14.5 136.8 ± 17.2 0.001
Platelet count (× 109/L) 166.1 ± 98.5 209.1 ± 79.0  < 0.001
MPV (fL) 10.9 ± 1.3 9.9 ± 1.5  < 0.001
PDW (%) 14.3 ± 2.5 14.8 ± 2.5 0.032
AST (U/L) 33 (24–45) 27 (20–40) 0.002
ALT (U/L) 33 (21–49) 26 (17–47) 0.036
γ-GGT (U/L) 58 (33–104) 80 (36–185) 0.002
Total bilirubin (μmol/L) 15.3 (11.8–20.1) 13.5 (10.2–16.8) 0.001
AFP (ng/mL) 19.4 (4.4–425.0) 3.2 (1.87–6.07)  < 0.001
CA19-9 (U/mL) 16.4 (9.5–31.1) 44.2 (20.2–470.2)  < 0.001
FIB-4 2.1 (1.4–3.2) 1.5 (1.1–2.4)  < 0.001
APRI 0.5 (0.3–1.0) 0.4 (0.2–0.6)  < 0.001
NLR 1.99 ± 1.36 3.58 ± 1.75 0.001
Validation set
N 107 51  
Age (years) 52.7 ± 10.2 58.8 ± 9.6  < 0.001
BMI (kg/m2) 22.0 ± 2.6 22.7 ± 2.3 0.082
Sex (male, %) 80 (74.8) 22 (43.1)  < 0.001
HBsAg (%) 63 (58.9) 11 (21.6)  < 0.001
Hepatitis C (%) 1 (0.9) 3 (5.9) 0.064
Cirrhosis (%) 50 (46.7) 16 (31.4) 0.067
Tumor number (Multiple, %) 18 (16.8) 5 (9.8) 0.242
The largest nodule diameter (cm) 6.4 ± 4.2 6.8 ± 5.6 0.636
Capsule (Incomplete, %) 32 (29.9) 25 (49.0) 0.019
WBC (× 109/L) 8.14 ± 3.58 8.75 ± 5.00 0.382
Haemoglobin (g/L) 121.8 ± 23.7 130.8 ± 18.7 0.018
Platelet count (× 109/L) 178.2 ± 91.5 252.3 ± 98.8  < 0.001
MPV (fL) 11.2 ± 1.0 10.3 ± 0.9  < 0.001
PDW (%) 13.2 ± 2.2 13.5 ± 2.0 0.431
AST (U/L) 38 (26–61) 55 (25–122) 0.062
ALT (U/L) 50 (30–87) 93 (27–169) 0.058
γ-GGT (U/L) 78 (42–137) 158 (66–413)  < 0.001
Total bilirubin (μmol/L) 18.2 (14.0–25.4) 47.0 (16.5–137.1)  < 0.001
AFP (ng/mL) 23.7 (4.7–482.4) 2.8 (1.6–3.7)  < 0.001
CA19-9 (U/mL) 16.7 (6.8–32.1) 96.6 (28.8–285.7)  < 0.001
FIB-4 2.0 (1.1–3.3) 1.6 (1.0–2.8)  < 0.001
APRI 0.7 (0.3–1.2) 0.7 (0.3–1.4) 0.132
NLR 3.96 ± 1.76 4.17 ± 1.32 0.548
  1. Data are expressed as means (SD) or percentage. SD, standard deviation; BMI, body mass index; HBsAg, hepatitis B surface antigen; WBC, white blood cell count; MPV, mean platelet volume; PDW, platelet distribution width; AST, aspartate transaminase; ALT, alanine transaminase; γ-GGT, γ-glutamyl transferase; AFP, alphafetoprotein; CA19-9, carbohydrate antigen 19–9; APRI, aspartate aminotransferase/platelet ratio index; FIB-4, fibrosis-4; NLR, neutrophil-to-lymphocyte ratio. Bold indicates statistically significant values (P < 0.05)